Opportunity Information: Apply for CDC RFA IP16 1606
Apply for CDC RFA IP16 1606
- The HHS-CDC-NCIRD in the health sector is offering a public funding opportunity titled "Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.318.
- This funding opportunity was created on May 17, 2016 and posted on May 17, 2016.
- Applicants must submit their applications by Jul 18, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization" (Funding Opportunity Number CDC-RFA-IP16-1606) is a discretionary cooperative agreement offered by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (HHS-CDC), specifically through NCIRD. Its purpose is to fund World Health Organization (WHO) Regional Offices to lead and coordinate efforts that help countries strengthen their ability to track, understand, and respond to influenza threats, including both routine seasonal influenza and emerging novel influenza viruses with pandemic potential.
At the core of the opportunity is a coordinated regional plan, implemented by WHO Regional Offices, aimed at supporting national governments and regional public health authorities. The emphasis is on improving influenza surveillance systems by building and enhancing capacity in two key areas: laboratory surveillance and epidemiologic surveillance. In practical terms, this means strengthening the ability of countries to detect influenza viruses through lab testing, characterize circulating strains, and connect those laboratory findings with field-based data on illness patterns, transmission, and severity. By improving both lab and epidemiologic components, the program is designed to make surveillance more reliable, comparable across countries, and useful for real-time decision-making.
Another major goal is helping countries develop straightforward, workable methods to estimate the burden of influenza disease. The opportunity recognizes that many settings need simple approaches that can be sustained over time, rather than complex studies that are difficult to repeat. The grant supports using surveillance data and other routinely collected information to determine how much illness and severe disease influenza is causing at country and regional levels. This burden information is intended to translate surveillance findings into evidence that health leaders can use for planning, prioritization, and policy.
The opportunity also prioritizes improving readiness to detect and respond to outbreaks of novel influenza viruses that could spark a pandemic. It explicitly references threats like highly pathogenic avian influenza and swine-origin influenza viruses, reflecting the intent to strengthen early warning and rapid response capacity for unusual or high-consequence events. This includes improving the systems and technical capacity needed to recognize atypical influenza signals, confirm them through laboratory methods, share information efficiently, and support timely public health actions when a potential pandemic threat emerges.
In addition to surveillance and outbreak response, the program is designed to support country activities that inform vaccine policy. A key expected outcome is better evidence to guide decisions about introducing influenza vaccines where they are not yet widely used, and expanding their use where programs exist but could be strengthened. By linking surveillance and burden estimates to policy discussions, the grant aims to help countries make data-driven choices about vaccination strategies, target groups, and program scale, using locally relevant evidence rather than relying only on external assumptions.
From an administrative standpoint, the funding instrument is a cooperative agreement, which typically indicates a substantial level of involvement by the funding agency in collaboration, technical input, and program coordination during implementation. The opportunity falls under the health funding activity category and is associated with CFDA number 93.318. The eligibility category is listed as "Others," with the text clarifying that WHO Regional Offices are the intended recipients. The award ceiling is $2,000,000, with an expectation of about six awards, signaling an intent to support multiple WHO regions or multi-country regional groupings rather than a single global award.
Key dates listed for the opportunity include a creation and posting date of May 17, 2016, with an application closing date of July 18, 2016. Overall, the grant is structured to strengthen influenza surveillance and response capacity through WHO regional leadership, improve the ability to measure influenza disease burden with practical methods, enhance detection and response to novel influenza outbreaks with pandemic potential, and generate evidence that supports sound influenza vaccine policy decisions across countries and regions.
FAQs: Surveillance and Response to Seasonal and Pandemic Influenza by WHO Regional Offices (CDC-RFA-IP16-1606)
1) What is the title of this grant opportunity?
The opportunity is titled "Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization."
2) What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is CDC-RFA-IP16-1606.
3) Which agency is offering this funding?
This is a discretionary cooperative agreement offered by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (HHS-CDC), specifically through NCIRD.
4) What type of funding mechanism is used?
The funding instrument is a cooperative agreement, which typically indicates substantial involvement by the funding agency in collaboration, technical input, and program coordination during implementation.
5) Who is eligible to apply?
The eligibility category is listed as "Others," and the intended recipients are WHO Regional Offices.
6) What is the main purpose of the grant?
The purpose is to fund WHO Regional Offices to lead and coordinate efforts that help countries strengthen their ability to track, understand, and respond to influenza threats, including routine seasonal influenza and emerging novel influenza viruses with pandemic potential.
7) What are the core activities supported by this opportunity?
The opportunity centers on implementing a coordinated regional plan led by WHO Regional Offices to support national governments and regional public health authorities, with a strong emphasis on strengthening influenza surveillance and response capacity.
8) What parts of influenza surveillance are emphasized?
The program emphasizes improving influenza surveillance systems by building and enhancing capacity in two key areas: laboratory surveillance and epidemiologic surveillance.
9) What does "laboratory surveillance" mean in this program?
Laboratory surveillance refers to strengthening the ability of countries to detect influenza viruses through lab testing and to characterize circulating influenza strains.
10) What does "epidemiologic surveillance" mean in this program?
Epidemiologic surveillance refers to connecting laboratory findings with field-based data on illness patterns, transmission, and severity to make surveillance more useful for public health action.
11) Why does the opportunity focus on both lab and epidemiologic surveillance?
By improving both components, the program aims to make surveillance more reliable, comparable across countries, and useful for real-time decision-making.
12) Does the program support estimating the burden of influenza disease?
Yes. A major goal is helping countries develop straightforward, workable methods to estimate the burden of influenza disease.
13) What kind of burden estimation methods are encouraged?
The opportunity recognizes that many settings need simple approaches that can be sustained over time, rather than complex studies that are difficult to repeat. It supports using surveillance data and other routinely collected information to estimate how much illness and severe disease influenza is causing at country and regional levels.
14) How is burden information expected to be used?
Burden information is intended to translate surveillance findings into evidence health leaders can use for planning, prioritization, and policy.
15) Does this opportunity address pandemic preparedness?
Yes. The program prioritizes improving readiness to detect and respond to outbreaks of novel influenza viruses that could spark a pandemic.
16) What novel influenza threats are referenced?
The opportunity explicitly references threats like highly pathogenic avian influenza and swine-origin influenza viruses.
17) What kinds of capabilities are meant to be strengthened for novel influenza detection and response?
This includes improving systems and technical capacity to recognize atypical influenza signals, confirm them through laboratory methods, share information efficiently, and support timely public health actions when a potential pandemic threat emerges.
18) Does the grant support work related to influenza vaccine policy?
Yes. In addition to surveillance and outbreak response, the program is designed to support country activities that inform vaccine policy.
19) What vaccine-policy outcomes are expected?
A key expected outcome is better evidence to guide decisions about introducing influenza vaccines where they are not yet widely used, and expanding their use where programs exist but could be strengthened.
20) How does the program connect surveillance to vaccine decision-making?
It links surveillance and burden estimates to policy discussions so countries can make data-driven choices about vaccination strategies, target groups, and program scale using locally relevant evidence.
21) What is the funding activity category?
The opportunity falls under the health funding activity category.
22) What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA number 93.318.
23) What is the maximum award amount (award ceiling)?
The award ceiling is $2,000,000.
24) How many awards are expected?
Approximately six awards are expected.
25) What does the expected number of awards suggest about how funding will be distributed?
It signals an intent to support multiple WHO regions or multi-country regional groupings rather than a single global award.
26) When was the opportunity created and posted?
The creation and posting date is May 17, 2016.
27) What was the application closing date?
The application closing date is July 18, 2016.
28) Who is expected to lead and coordinate the regional work funded by this grant?
WHO Regional Offices are expected to lead and coordinate the work through a coordinated regional plan that supports national governments and regional public health authorities.
29) What is the overall intent of the program in one summary?
The grant is structured to strengthen influenza surveillance and response capacity through WHO regional leadership, improve practical methods to measure influenza disease burden, enhance detection and response to novel influenza outbreaks with pandemic potential, and generate evidence that supports sound influenza vaccine policy decisions across countries and regions.
Browse more opportunities from the same agency: HHS-CDC-NCIRD
Browse more opportunities from the same category: Health
Next opportunity: NOTICE OF INTENT TO AWARD - The Essex National Heritage Area
Previous opportunity: Food Web Analysis of the Methow River and its Floodplain
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA IP16 1606
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA IP16 1606) also looked into and applied for these:
| Funding Opportunity |
|---|
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP16 1604 Funding Number: CDC RFA IP16 1604 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $250,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 16 269 Funding Number: PAR 16 269 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01) Apply for RFA AI 16 047 Funding Number: RFA AI 16 047 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03) Apply for PAR 16 268 Funding Number: PAR 16 268 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 16 270 Funding Number: PAR 16 270 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 16 272 Funding Number: PAR 16 272 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 16 271 Funding Number: PAR 16 271 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 17 008 Funding Number: HRSA 17 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) Apply for CDC RFA PS14 140204CONT17 Funding Number: CDC RFA PS14 140204CONT17 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| CDC’s National Undergraduate Student Program: A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110106CONT16 Funding Number: CDC RFA MN11 110106CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Fogarty Global Health Training Program (D43) Apply for RFA TW 16 002 Funding Number: RFA TW 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Surveillance, intervention, and referral to services activities for infants with microcephaly or other adverse outcomes linked with the Zika virus Apply for CDC RFA DD16 1605 Funding Number: CDC RFA DD16 1605 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $360,000 |
| Developing New Clinical Decision Support to Disseminate and Implement Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 282 Funding Number: PA 16 282 Agency: HHS-AHRQ Category: Health Funding Amount: $750,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Specialized Center Cooperative Agreements (U54) Apply for RFA OD 16 011 Funding Number: RFA OD 16 011 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Comprehensive Platform for Integrated Communication Initiative (CPICI) Apply for RFA 621 16 000003 Funding Number: RFA 621 16 000003 Agency: USAID-TAN Category: Health Funding Amount: $46,200,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Resource Cooperative Agreement (U42) Apply for RFA OD 16 012 Funding Number: RFA OD 16 012 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Scaling Established Clinical Decision Support to Facilitate the Dissemination and Implementation of Patient-Centered Outcomes Research Findings (R18) Apply for PA 16 283 Funding Number: PA 16 283 Agency: HHS-AHRQ Category: Health Funding Amount: $500,000 |
| Establishment of Centers of Excellence in Refugee Health Apply for CDC RFA CK12 120505CONT16 Funding Number: CDC RFA CK12 120505CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Addressing Ebola and other Highly Infectious Diseases Internationally Apply for CDC RFA CK15 15050203SUPP16 Funding Number: CDC RFA CK15 15050203SUPP16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| Systems Approach to Immunity and Inflammation (U19) Apply for RFA AI 16 050 Funding Number: RFA AI 16 050 Agency: HHS-NIH11 Category: Health Funding Amount: $1,500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA IP16 1606", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.